$ELOX

Analysts initiated coverage on several companies: Piper Sandler rated Redwire Corp (RDW) Neutral with a $11 target, Cantor Fitzgerald rated Eloxx Pharmaceuticals (ELOX) Overweight, HC Wainwright rated Sight Sciences (SGHT) Buy with a $14 target, Goldman Sachs rated Anglogold Ashanti (AU) Buy with a $104 target, and Raymond James rated First Financial Bankshares (FFIN) Market Perform.

Eloxx Pharmaceuticals (ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome. Topline data is expected mid-2027, with a final readout by year-end 2027. The trial aims to evaluate exaluren's safety and efficacy in 24 patients.

Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.

Eloxx Pharmaceuticals reported a wider Q2 2026 loss of $4.5M, up from $1.9M a year ago, due to higher R&D and G&A expenses. The company raised $58.3M in a public offering and uplisted to Nasdaq. Eloxx plans to start a Phase 2b trial for exaluren in Q3 2026, with data expected in 2027. The stock is up 18.10% to $21.31.

Eloxx Pharmaceuticals, Inc. reported Schedule 13G filings showing Samsara BioCapital and its affiliates each hold 201,793 shares, about 5.0% of Eloxx common stock. Dr. Srinivas Akkaraju reports 403,586 shares, 9.99%, based on 4,036,314 shares outstanding as of June 10, 2026. Pre-funded warrants include a 9.99% beneficial ownership blocker.

Eloxx Pharmaceuticals (Nasdaq: ELOX) reported Q2 2026 results and a business update. It completed a $66.0 million underwritten public offering and uplisted to Nasdaq (symbol ELOX). Cash was $62.0 million at June 30, 2026. Phase 2b exaluren in nonsense mutation Alport syndrome is expected to start Q3 2026; ADPKD trial planned for 2027. Net loss was $4.5 million.

Eloxx Pharmaceuticals, Inc. (ELOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company’s balanc

Biotech shares hit 52-week highs on Aug. 3-4, 2026, led by catalysts including upcoming quarterly reports and clinical-trial updates. AngioDynamics (ANGO) reached $15.41, citing FDA clearance for its RELIEF study and FY2026 net sales of $320.2 million. Anika (ANIK) hit $21.11 after Q2 revenue rose to $32.6 million. Pulse (PLSE) rose to $38.29 ahead of Aug. 6 results; Eloxx (ELOX) and Yarrow (YARW) also reached highs.